{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:07:30Z","timestamp":1791313650446,"version":"4.3.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Bristol-Myers Squibb Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40272-020-00422-2","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T03:33:24Z","timestamp":1602128004000},"page":"653-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Nys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzuyung D.","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Dominique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"issue":"2","key":"422_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"9563","key":"422_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet"},{"issue":"5","key":"422_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/BOR.0000000000000206","volume":"27","author":"K Webb","year":"2015","unstructured":"Webb K, Wedderburn LR. Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol. 2015;27(5):505\u201310.","journal-title":"Curr Opin Rheumatol"},{"issue":"9783","key":"422_CR4","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138\u201349.","journal-title":"Lancet"},{"issue":"1","key":"422_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.22473","volume":"57","author":"S Oliveira","year":"2007","unstructured":"Oliveira S, Ravelli A, Pistorio A, Castell E, Malattia C, Prieur AM, et al. Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum. 2007;57(1):35\u201343.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"422_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717\u201334.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"7","key":"422_CR7","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"422_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658\u201366.","journal-title":"Arthritis Rheum"},{"key":"422_CR9","unstructured":"Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol. 2001;19(4 Suppl 23):S1\u2013S9."},{"issue":"7","key":"422_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1136\/annrheumdis-2011-200237","volume":"71","author":"EB Nordal","year":"2012","unstructured":"Nordal EB, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis. 2012;71(7):1122\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"422_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2352-4642(18)30034-8","volume":"2","author":"N Ruperto","year":"2018","unstructured":"Ruperto N, Martini A. Current and future perspectives in the management of juvenile idiopathic arthritis. Lancet Child Adolesc Health. 2018;2(5):360\u201370.","journal-title":"Lancet Child Adolesc Health."},{"key":"422_CR12","unstructured":"Bristol-Myers Squibb Canada. ORENCIA\u00ae (abatacept) product monograph. 2019. https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/ORENCIA_EN_PM.pdf. Accessed 9 June 2019."},{"issue":"11","key":"422_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrrheum.2009.209","volume":"5","author":"C Macaubas","year":"2009","unstructured":"Macaubas C, Nguyen K, Milojevic D, Park JL, Mellins ED. Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol. 2009;5(11):616.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"422_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459\u201365.","journal-title":"J Exp Med"},{"issue":"6","key":"422_CR15","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","volume":"183","author":"TL Walunas","year":"1996","unstructured":"Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996;183(6):2541\u201350.","journal-title":"J Exp Med"},{"issue":"10","key":"422_CR16","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/rheumatology\/kex238","volume":"56","author":"J Morel","year":"2017","unstructured":"Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford). 2017;56(10):1746\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"422_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaut.2019.04.016","volume":"101","author":"R Lorenzetti","year":"2019","unstructured":"Lorenzetti R, Janowska I, Smulski CR, Frede N, Henneberger N, Walter L, et al. Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells. J Autoimmun. 2019;101:145\u201352.","journal-title":"J Autoimmun"},{"key":"422_CR18","unstructured":"European Medicines Agency. Orencia authorisation details. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orencia#authorisation-details-section. Accessed 9 June 2019."},{"key":"422_CR19","unstructured":"Bristol-Myers Squibb. Orencia (abatacept) prescribing information. 2019."},{"issue":"7","key":"422_CR20","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/art.40466","volume":"70","author":"HI Brunner","year":"2018","unstructured":"Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, Penad\u00e9s IC, et al. Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Arthritis Rheumatol. 2018;70(7):1144\u201354.","journal-title":"Arthritis Rheumatol."},{"issue":"9636","key":"422_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383\u201391.","journal-title":"Lancet"},{"issue":"10","key":"422_CR22","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1002\/art.39234","volume":"67","author":"D Lovell","year":"2015","unstructured":"Lovell D, Ruperto N, Mouy R, Paz E, Rubio-P\u00e9rez N, Silva CA, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015;67(10):2759\u201370.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"422_CR23","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/art.27431","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1792\u2013802.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"422_CR24","first-page":"1058","volume":"29","author":"HI Brunner","year":"2002","unstructured":"Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol. 2002;29(5):1058\u201364.","journal-title":"J Rheumatol"},{"issue":"1","key":"422_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12969-019-0319-4","volume":"17","author":"R Hara","year":"2019","unstructured":"Hara R, Umebayashi H, Takei S, Okamoto N, Iwata N, Yamasaki Y, et al. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Ped Rheum. 2019;17(1):17.","journal-title":"Ped Rheum."},{"key":"422_CR26","unstructured":"Li X, Passarell JA, Lin K, Roy A, Murthy B, Girgis IG. Population pharmacokinetics and exposure-response analyses for abatacept in juvenile idiopathic arthritis. Presented at: American Conference on Pharmacometrics (ACoP8); October 15\u201318, 2017; Fort Lauderdale, FL, USA. Poster W-069."},{"issue":"Suppl 2","key":"422_CR27","first-page":"138","volume":"75","author":"N Ruperto","year":"2016","unstructured":"Ruperto N, Lovell DJ, Tzaribachez N, Vega-Cornejo G, Louw I, Berman A, et al. Subcutaneous abatacept in patients with polyarticular juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs: pharmacokinetics, efficacy and safety. Ann Rheum Dis. 2016;75(Suppl 2):138.","journal-title":"Ann Rheum Dis"},{"key":"422_CR28","unstructured":"Zhou Z, Roy A, Murthy B, Gao L, Teng J, Kaul S et al. Relationship between systemic exposure and the efficacy and safety of abatacept administered subcutaneously and intravenously in adult rheumatoid arthritis patients. Presented at: American Association of Pharmaceutical Scientists National Biotechnology Conference; May 16\u201318, 2011; San Francisco, CA, USA. Poster W3101."},{"issue":"6","key":"422_CR29","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.39583","volume":"68","author":"E Demirkaya","year":"2016","unstructured":"Demirkaya E, Lanni S, Bovis F, Galasso R, Ravelli A, Palmisani E, et al. A meta-analysis to sstimate the placebo effect in randomized controlled trials in juvenile idiopathic arthritis. Arthritis Rheumatol. 2016;68(6):1540\u201350.","journal-title":"Arthritis Rheumatol."},{"key":"422_CR30","unstructured":"Ruperto N, Lovell D, Bohnsack J, J B, Fischbach M, T L et al. Subcutaneous or intravenous abatacept monotherapy in pediatric patients with polyarticular-course JIA: results from two phase III trials. Arthritis Rheumatol. 2019;71(Suppl 10):abstract 1815."},{"issue":"Suppl 2","key":"422_CR31","first-page":"99","volume":"78","author":"N Ruperto","year":"2019","unstructured":"Ruperto N, Brunner H, Tzaribachev N, Louw I, Calvo I, Zapata F, et al. Maintenance of clinincal response in individual children with juvenile idiopathic arthritis treated with subcutaneous abatacept. Ann Rheum Dis. 2019;78(Suppl 2):99\u2013100.","journal-title":"Ann Rheum Dis"},{"key":"422_CR32","unstructured":"Ruperto N, Brunner HI, Vega-Cornejo G, Berman A, Cuttica RJ, Avila-Zapata F et al., editors. Subcutaneous abatacept in patients aged 2\u201317\u00a0years with juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs: results over 24\u00a0months by juvenile idiopathic arthritis disease category. Arthritis Rheumatol. 2018;70(suppl 10):abstract # 2378."},{"key":"422_CR33","doi-asserted-by":"crossref","unstructured":"Gutierrez-Suarez R, Pistorio A, Cespedes Cruz A, Norambuena X, Flato B, Rumba I et al. Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. Rheumatology (Oxford). 2007;46(2):314-320.","DOI":"10.1093\/rheumatology\/kel218"},{"issue":"11","key":"422_CR34","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/acr.20283","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2010;62(11):1542\u201351.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"12","key":"422_CR35","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.1780371209","volume":"37","author":"G Singh","year":"1994","unstructured":"Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37(12):1761\u20139.","journal-title":"Arthritis Rheum"},{"key":"422_CR36","unstructured":"Brunner H, Tzaribachev N, Louw I, Ant\u00f3n J, Viola D, Lauwerys B et al. Improvement in patient-reported outcomes in patients aged 2\u20135\u00a0years with polyarticular-course JIA treated with subcutaneous abatacept: 2-year results from a phase III international study. Arthritis Rheumatol. 2019;71(suppl 10):abstract 2707."},{"key":"422_CR37","doi-asserted-by":"crossref","unstructured":"Ruperto N, Brunner H, Cornejo GV, Berman A, Anton J, Cuttica R et al. Growth and development of patients with polyarticular-course juvenile idiopathic arthritis treated with subcutaneous abatacept. Ann Rheum Dis. 2019;78:1347\u20131350 (abstract SAT0515).","DOI":"10.1136\/annrheumdis-2019-eular.1485"},{"key":"422_CR38","unstructured":"Ruperto N, Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Foeldvari I et al. Antibody responses to diphtheria\/tetanus vaccine in paediatric patients with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatr Rheumatol Online J. 2018;16(Suppl 2):52 (abstract P252)."},{"issue":"1","key":"422_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-020-0410-x","volume":"18","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Tzaribachev N, Vega Cornejo G, Joos R, Gervais E, Cimaz R, et al. Maintenance of antibody response to diphtheria\/tetanus vaccine in patients aged 2\u20135\u00a0years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatr Rheumatol Online J. 2020;18(1):19.","journal-title":"Pediatr Rheumatol Online J."},{"key":"422_CR40","unstructured":"Brunner H, Tzaribachev N, Louw I, Berman A, Calvo Penad\u00e9s I, Ant\u00f3n J et al. Effect of immunogenicity on efficacy and safety of subcutaneous or intravenous abatacept in pediatric patients with polyarticular-course JIA: findings from two phase III trials. Arthritis Rheumatol. 2019;71(suppl 10):abstract 2708."},{"key":"422_CR41","unstructured":"PRCSG. Pediatric Rheumatology Collaborative Study Group. 2016. https:\/\/www.prcsg.org\/. Accessed 27 Apr 2020."},{"key":"422_CR42","unstructured":"PRINTO. Paediatric Rheumatology International Trials Organisation. 2020. https:\/\/printo.it\/. Accessed 27 Apr 2020."},{"key":"422_CR43","unstructured":"Ruperto N, Lovell D, Tzaribachev N, Zeft A, Cimaz R, Stanevica V et al. Longitudinal effectiveness of abatacept in juvenile idiopathic arthritis: results from an ongoing JIA registry. Presented at: European Paediatric Rheumatology Conference; September 5\u20138, 2018; Lisbon, Portugal; P384."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00422-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-020-00422-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00422-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T08:01:24Z","timestamp":1696838484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-020-00422-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s40272-020-00422-2","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"assertion":[{"value":"9 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Studies cited in this review were funded by Bristol-Myers Squibb Company. The review was commissioned by <i>Pediatric Drugs<\/i> and funded by Bristol-Myers Squibb Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"HIB: speaker fees: Novartis and Roche; grant\/research support: Bristol-Myers Squibb Company and Pfizer; consulting fees: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb Company, EMD Serono, Enzyvant, Genentech\/Roche, GlaxoSmithKline, Janssen, Lilly, Novartis, R-Pharm, and UCB. RW, MN, TDK, and AD: shareholders and stakeholders of Bristol-Myers Squibb Company. AM: consulting fees from Janssen, Novartis, and Pfizer. Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia has received consulting fees from AbbVie, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, EMD Serono, Janssen, Novartis, Pfizer, and R-Pharm for the work of AM. DJL: speakers\u2019 bureau: Bristol-Myers Squibb Company and Genentech; data and safety monitoring board: Forest Research and the National Institutes of Health-NIAMS. Cincinnati Children\u2019s Hospital Medical Center has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb Company, Centocor, F. Hoffmann-La Roche, Genentech, Novartis, Pfizer, Regeneron, UCB, and XOMA for the work of DJL. NR: grant\/research support (paid to the Istituto Giannina Gaslini Hospital): Bristol-Myers Squibb Company, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Swedish Orphan Biovitrum (Sobi) (this funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties); speaker fees\/honoraria: AbbVie, Ablynx, AstraZeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eli Lilly, EMD Serono, F. Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, R-Pharma, Sanofi, Servier, Sinergie, Sobi, and Takeda.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"HIB, AM, DJL, and NR had a pivotal and critical role in the design, implementation, analysis, and reporting of the intravenous and subcutaneous abatacept pivotal juvenile idiopathic arthritis trials. The manuscript was drafted and revised critically by the named authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}